BREAST CANCER: Blocking both driver and escape pathways improves outcomes

    loading  Checking for direct PDF access through Ovid


The BOLERO-2 and CLEOPATRA trials evaluated everolimus for estrogen receptor-positive and pertuzumab for HER2-positive metastatic breast cancer. Both agents enhanced the efficacy of standard therapy, were relatively well tolerated and should be approved for therapeutic use. These data confirm that targeting both major driver and escape pathways improves treatment outcomes.

Related Topics

    loading  Loading Related Articles